Bortezomib

Where the papers sit

15 papers from the last 6 months study bortezomib directly · updated from PubMed 10 Oct 2026

• Daratumumab-Based Frontline Myeloma

  Daratumumab-containing quadruplets are moving frontline treatment toward deeper responses and improved progression-free survival in newly diagnosed multiple myeloma. DVRd is being compared with VRd in transplant-eligible patients, while CEPHEUS extends minimal residual disease assessment to transplant-ineligible or deferred patients. Infection risk and combination safety remain important, particularly with lenalidomide and dexamethasone. The evidence also highlights caution when interpreting interim trial analyses.

  5 papers · 33.3%

• Myeloma Treatment and Renal Recovery

  Deep hematologic responses are increasingly linked to renal recovery in multiple myeloma, including patients presenting with renal impairment. Pomalidomide, bortezomib, and dexamethasone are being evaluated in this setting, while selinexor-based combinations target high-risk newly diagnosed disease. Daratumumab-based therapy also shows durable survival benefit in amyloidosis. Circulating M-MDSC expansion may provide a response-associated biomarker, but the required depth and speed of response for renal rescue remain open questions.

  5 papers · 33.3%

• Proteasome-Inhibitor Response Biology

  Bortezomib sensitivity is being linked to ferroptosis, DNA-repair failure, PI3K/Akt inhibition, and reversal of tumor-associated immune suppression. MYBL2 knockdown, triptonide, tocotrienol, and syndecan-1-targeting strategies are being explored as ways to enhance antitumor activity or overcome resistance. The evidence is predominantly mechanistic and preclinical, spanning multiple myeloma and colorectal cancer. Genetic studies of bortezomib-induced peripheral neuropathy broaden the focus from efficacy toward treatment toxicity and patient susceptibility.

  5 papers · 33.3%